A5041985632- Acute Myeloid Leukemia Research
- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Lymphoma Diagnosis and Treatment
- Hematological disorders and diagnostics
- Histone Deacetylase Inhibitors Research
- Eosinophilic Disorders and Syndromes
- Cloud Computing and Resource Management
- Protein Degradation and Inhibitors
- Software System Performance and Reliability
- Platelet Disorders and Treatments
- Bone health and treatments
- Renal and Vascular Pathologies
- Cancer, Stress, Anesthesia, and Immune Response
- Prion Diseases and Protein Misfolding
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Chemotherapy-related skin toxicity
- Eosinophilic Esophagitis
- Pneumocystis jirovecii pneumonia detection and treatment
- Blood disorders and treatments
- RNA regulation and disease
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Renal Diseases and Glomerulopathies
The University of Texas MD Anderson Cancer Center
2021-2025
The Ohio State University Wexner Medical Center
2024
The Ohio State University
2023
University of Houston
2022
Cognizant (United States)
2011
Introduction: RAS pathway mutations are common mechanisms of resistance to acute myeloid leukemia (AML) therapies. Trametinib, an oral MEK inhibitor, has been shown have single-agent activity in relapsed/refractory AML and preclinical synergy with venetoclax. Methods: We conducted a single-center, open-label, phase 2 trial the combination azacitidine, venetoclax, trametinib patients relapsed or refractory harboring pathway-activating mutation. Results: Sixteen were treated. The heavily...
<title>Abstract</title> Pirtobrutinib is a reversible Bruton’s tyrosine kinase (BTK) inhibitor that has shown efficacy for patients with chronic lymphocytic leukemia (CLL) in BRUIN trial. These were previously treated covalent BTK (cBTKi) and either discontinued cBTKi or had disease progression during therapy. As result, some wild-type while others mutant (mostly C481 site where binds). All received pirtobrutinib monotherapy. Twenty-six CLL from at MD Anderson twenty-three followed up least...
Abstract Purpose: Hypomethylating agents (HMA) combined with venetoclax are an emerging therapeutic strategy for higher-risk myelodysplastic syndromes (HR-MDS). The cytogenetic and molecular factors associated outcomes this combination HR-MDS incompletely understood. Experimental Design: We pooled patient data from 3 prospective trials evaluating HMA–venetoclax in to study associations between overall response rate (ORR), survival (OS), event-free (EFS). Kaplan–Meier method was used estimate...
AML presenting with hyperleukocytosis is associated poor outcomes. We aim to understand the factors early mortality and overall survival (OS) help guide management improve mortality.
Key Clinical Message Acute leukemia, particularly AML, is closely associated with thrombotic events, driven by complex factors like coagulation system changes, endothelial dysfunction, and leukemic cell interactions the vascular system. Certain chemotherapy drugs can exacerbate prothrombotic state. Understanding these dynamics crucial for effective thromboprophylaxis in carefully selected patients leukemia. Abstract Thrombosis a significant complication of acute Thrombotic events mostly...
Capillary leak syndrome (CLS) is characterized by plasma extravasation into the interstitium with resultant hypotension, anasarca, hemoconcentration, and hypoalbuminemia in absence of albuminuria. Initially reported Clarkson’s disease (systemic capillary syndrome), CLS has been observed multiple settings, most common being sepsis. In oncology, more often as a complication from therapy, less malignancy. this case study, we documented clinical manifestation, laboratory features, radiological...
Merkel cell cancer (MCC) is a rare cutaneous malignancy arising from neuroendocrine cells. This but lethal (mortality greater than 30%) has also tripled in incidence over the last two decades. The role of immunodeficiency pathogenesis this well established, with elucidation viral by polyoma virus (MCPyV), novel virus, majority patients. Viral neoantigens while playing an important oncogenesis can aid early immunologic detection recurrent disease. be targets for immunotherapy. Immune...
e19068 Background: The prognosis of patients with higher-risk (HR) MDS after hypomethylating agent (HMA) failure is poor a survival 4-6 months (Garcia-Manero et al, Lancet Oncology 2016). combination azacitidine (Aza) venetoclax (Ven) in frontline HR very active (Garcia JS ASH 2021). Methods: This phase 1 study evaluating ≥ 18 years old HMA adequate organ function and performance status were enrolled. was defined as relapse or progression 4 cycles HMA. Patients prior Ven exposure excluded....
Background: Pirtobrutinib, a highly selective, non-covalent (reversible) BTKi, demonstrated broad efficacy in patients (pts) with CLL/SLL who were resistant to cBTKi. Mechanisms of resistance pirtobrutinib have not been systematically analyzed date. Aims: To explore the genomic evolution cBTKi pre-treated pts. Methods: CLL pts treated monotherapy phase 1/2 BRUIN trial (NCT03740529) subsequently developed disease progression (PD) included this analysis. Targeted next-generation sequencing...
Chronic myelomonocytic leukemia (CMML) is a rare clonal stem cell disorder associated with clinical and pathologic of myelodysplasia myeloproliferation. Systemic autoimmune/inflammatory disorders (SAID) polyserositis have been CMML. These manifestations can be observed concomitantly, shortly before diagnosis or anytime along the course illness. We report case myeloproliferative CMML who presented positive serology for rheumatoid arthritis. Retrospective studies myelodysplasia/CMML reported...
Enterprises use design best practices to build applications that leverage the linear scalability of cloud. These include methods like data sharding, application denormalized stores, thin binary images etc. The itself involve reengineering an view activities as a business risk and costly affair. As Service oriented increasingly get migrated cloud, it is imperative utilize power multicore based host hardware, maintain or improve performance these in This paper presents methodology, through...
A 52-year-old Caucasian woman on pembrolizumab maintenance after induction with chemotherapy (carboplatin, pemetrexed) and for stage 4 non–small cell lung cancer was admitted increasing weakness. She had presented to emergency similar complaints 2 weeks earlier, she hydrated normal saline sent home antibiotics urinary tract infection. reported worsening weakness, anorexia weight loss of 12 pounds over 3 months. Her other medical problems include chronic pain depression. Home medications...
Abstract Advent of tyrosine kinase inhibitors (TKI) have revolutionized therapy chronic myeloid leukemia. Imatinib was the first agent utilized in CML. Nilotinib, a second generation TKI, results an increase number patients achieving major molecular response at earlier time point. Asymptomatic elevations pancreatic enzyme is common and acute pancreatitis within weeks to months from start has been observed. Delayed onset not reported. We report case delayed patient with sustained complete...
Statins work synergistically with androgen receptor blockers and biosynthesis inhibitors, improving survival in patients metastatic castration resistant prostate cancers (mCRPCs). Survival improvement is more pronounced for receiving inhibitors compared blockers. A rare adverse interaction between simvastatin abiraterone (Zytiga), an inhibitor, was observed a patient mCRPC due to pharmacokinetic changes resulting from obstructive jaundice.
Diffuse carcinomatosis of the bone marrow (DCBM) is a rare clinical condition characterized by diffuse involvement with hematological changes. This case study concerns patient who presented DCBM secondary to colon cancer intravascular coagulation. presentation in cancer. The also elaborates on features, pathogenesis, and therapy this unique presentation.
Abstract Covalent Bruton tyrosine kinase inhibitors (cBTKis), which bind to the BTK C481 residue, are now primary therapeutics for chronic lymphocytic leukemia (CLL). Alterations at C481, primarily C481S, prevent cBTKi binding and lead emergence of resistant clones. Pirtobrutinib is a noncovalent BTKi that binds both wild-type (WT) C481S-mutated has shown efficacy in BTK-WT -mutated CLL patient groups. To compare baseline clinical, transcriptomic, proteomic characteristics their changes...